Recombinant adeno-associated virus mediates a high level of gene transfer but less efficient integration in the K562 human hematopoietic cell line - PubMed (original) (raw)
Recombinant adeno-associated virus mediates a high level of gene transfer but less efficient integration in the K562 human hematopoietic cell line
P Malik et al. J Virol. 1997 Mar.
Abstract
We tested the ability of a recombinant adeno-associated virus (rAAV) vector to express and integrate exogenous DNA into human hematopoietic cells in the absence of selection. We developed an rAAV vector, AAV-tNGFR, carrying a truncated rat nerve growth factor receptor (tNGFR) cDNA as a cell surface reporter under the control of the Moloney murine leukemia virus (MoMuLV) long terminal repeat. An analogous MoMuLV-based retroviral vector (L-tNGFR) was used in parallel, and gene transfer and expression in human hematopoietic cells were assessed by flow cytometry and DNA analyses. Following gene transfer into K562 cells with AAV-tNGFR at a multiplicity of infection (MOI) of 13 infectious units (IU), 26 to 38% of cells expressed tNGFR on the surface early after transduction, but the proportion of tNGFR expressing cells steadily declined to 3.0 to 3.5% over 1 month of culture. At an MOI of 130 IU, nearly all cells expressed tNGFR immediately posttransduction, but the proportion of cells expressing tNGFR declined to 62% over 2 months of culture. The decline in the proportion of AAV-tNGFR-expressing cells was associated with ongoing losses of vector genomes. In contrast, K562 cells transduced with the retroviral vector L-tNGFR expressed tNGFR in a constant fraction. Integration analyses on clones showed that integration occurred at different sites. Integration frequencies were estimated at about 49% at an MOI of 130 and 2% at an MOI of 1.3. Transduction of primary human CD34+ progenitor cells by AAV-tNGFR was less efficient than with K562 cells and showed a declining percentage of cells expressing tNGFR over 2 weeks of culture. Thus, purified rAAV caused very high gene transfer and expression in human hematopoietic cells early after transduction, which steadily declined during cell passage in the absence of selection. Although the efficiency of integration was low, overall integration was markedly improved at a high MOI. While prolonged episomal persistence may be adequate for gene therapy of nondividing cells, a very high MOI or improvements in basic aspects of AAV-based vectors may be necessary to improve integration frequency in the rapidly dividing hematopoietic cell population.
Similar articles
- Increased probability of expression from modified retroviral vectors in embryonal stem cells and embryonal carcinoma cells.
Robbins PB, Yu XJ, Skelton DM, Pepper KA, Wasserman RM, Zhu L, Kohn DB. Robbins PB, et al. J Virol. 1997 Dec;71(12):9466-74. doi: 10.1128/JVI.71.12.9466-9474.1997. J Virol. 1997. PMID: 9371608 Free PMC article. - Recombinant adeno-associated virus-mediated gene transfer into hematopoietic progenitor cells.
Goodman S, Xiao X, Donahue RE, Moulton A, Miller J, Walsh C, Young NS, Samulski RJ, Nienhuis AW. Goodman S, et al. Blood. 1994 Sep 1;84(5):1492-500. Blood. 1994. PMID: 8068942 - Integration of adeno-associated virus (AAV) and recombinant AAV vectors.
McCarty DM, Young SM Jr, Samulski RJ. McCarty DM, et al. Annu Rev Genet. 2004;38:819-45. doi: 10.1146/annurev.genet.37.110801.143717. Annu Rev Genet. 2004. PMID: 15568995 Review. - [Integration of AAV vectors and insertional mutagenesis].
Rossi A, Salvetti A. Rossi A, et al. Med Sci (Paris). 2016 Feb;32(2):167-74. doi: 10.1051/medsci/20163202010. Epub 2016 Mar 2. Med Sci (Paris). 2016. PMID: 26936174 Review. French.
Cited by
- AAV-based neonatal gene therapy for hemophilia A: long-term correction and avoidance of immune responses in mice.
Hu C, Lipshutz GS. Hu C, et al. Gene Ther. 2012 Dec;19(12):1166-76. doi: 10.1038/gt.2011.200. Epub 2012 Jan 12. Gene Ther. 2012. PMID: 22241178 Free PMC article. - Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques.
Johnson PR, Schnepp BC, Connell MJ, Rohne D, Robinson S, Krivulka GR, Lord CI, Zinn R, Montefiori DC, Letvin NL, Clark KR. Johnson PR, et al. J Virol. 2005 Jan;79(2):955-65. doi: 10.1128/JVI.79.2.955-965.2005. J Virol. 2005. PMID: 15613324 Free PMC article. - Design and packaging of adeno-associated virus gene targeting vectors.
Hirata RK, Russell DW. Hirata RK, et al. J Virol. 2000 May;74(10):4612-20. doi: 10.1128/jvi.74.10.4612-4620.2000. J Virol. 2000. PMID: 10775597 Free PMC article. - Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes.
Lieber A, Steinwaerder DS, Carlson CA, Kay MA. Lieber A, et al. J Virol. 1999 Nov;73(11):9314-24. doi: 10.1128/JVI.73.11.9314-9324.1999. J Virol. 1999. PMID: 10516040 Free PMC article. - Adeno-Associated Virus Vectors and Stem Cells: Friends or Foes?
Brown N, Song L, Kollu NR, Hirsch ML. Brown N, et al. Hum Gene Ther. 2017 Jun;28(6):450-463. doi: 10.1089/hum.2017.038. Hum Gene Ther. 2017. PMID: 28490211 Free PMC article. Review.
References
- J Virol. 1983 Feb;45(2):555-64 - PubMed
- Gene Ther. 1995 Jul;2(5):336-43 - PubMed
- Mol Cell Biol. 1986 Aug;6(8):2895-902 - PubMed
- J Virol. 1996 May;70(5):3227-34 - PubMed
- J Virol. 1996 Oct;70(10):6759-66 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources